Indication

Hypogonadotropic hypogonadism

Hypogonadotropic hypogonadism, also known as secondary or central hypogonadism, is an endocrine disorder characterized by impaired gonadal function resulting from deficient stimulation by the hypothalamic-pituitary-gonadal axis. Read more about Hypogonadotropic hypogonadism

13 drugs 8 manufacturers

Advertisement

Drugs that treat it

Common Hypogonadotropic hypogonadism therapies.

Showing 1–9 of 13 drugs

Filter & compare in the drug finder →Opens the drug finder with Hypogonadotropic hypogonadism preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Hypogonadotropic hypogonadism.

Hypogonadotropic hypogonadism, also known as secondary or central hypogonadism, is an endocrine disorder characterized by impaired gonadal function resulting from deficient stimulation by the hypothalamic-pituitary-gonadal axis.

It affects both male and female pediatric and adult populations, stemming from congenital defects, genetic anomalies such as Kallmann syndrome, or acquired structural, functional, or systemic insults to the hypothalamus or anterior pituitary gland.

Pathophysiologically, insufficient secretion of gonadotropin-releasing hormone, luteinizing hormone, or follicle-stimulating hormone leads to abnormally low levels of circulating sex steroids.

Clinically, this manifests as delayed, arrested, or absent puberty in adolescents, and infertility, sexual dysfunction, decreased bone mineral density, and loss of secondary sexual characteristics in adults.

Personalize your experience

Follow Hypogonadotropic hypogonadism and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it